The Seer spinoff recently closed a $46 million funding round that it is using to support efforts in nucleic acid, proteomic, and metabolomic biomarker discovery.
Read the full article in GenomeWeb here.
May 16, 2024
As Multiomics Progresses, Data Challenges Come to the Fore
Lab-Testing Startups Brace for FDA Rule Change
May 11, 2024
Philip Ma, CEO & Founder, PrognomiQ